238 related articles for article (PubMed ID: 34320420)
21. Disparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma.
Alnajar A; Kareff SA; Razi SS; Rao JS; De Lima Lopes G; Nguyen DM; Villamizar N; Rodriguez E
JAMA Netw Open; 2023 Mar; 6(3):e234261. PubMed ID: 36951862
[TBL] [Abstract][Full Text] [Related]
22. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Spires T; Zalcman G
Ann Oncol; 2022 May; 33(5):488-499. PubMed ID: 35124183
[TBL] [Abstract][Full Text] [Related]
23. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
Zauderer MG; Kass SL; Woo K; Sima CS; Ginsberg MS; Krug LM
Lung Cancer; 2014 Jun; 84(3):271-4. PubMed ID: 24690410
[TBL] [Abstract][Full Text] [Related]
24. Nivolumab for the treatment of unresectable pleural mesothelioma.
Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
[No Abstract] [Full Text] [Related]
25. Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma.
Kim RY; Mitra N; Bagley SJ; Marmarelis ME; Haas AR; Rendle KA; Vachani A
JTO Clin Res Rep; 2021 Jun; 2(6):100188. PubMed ID: 34590032
[TBL] [Abstract][Full Text] [Related]
26. Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).
Rojas L; Cardona AF; Trejo-Rosales R; Zatarain-Barrón ZL; Ramírez-Tirado LA; Ruiz-Patiño A; Campos Gómez S; Corrales L; Oblitas G; Bacon L; Martín C; de Lima VCC; Freitas HC; Mas L; Vargas C; Carranza H; Otero J; Pérez MA; González L; Chirinos L; Granados ST; Rodriguez J; Báez R; Remolina Bonilla YA; Núñez Cerrillo G; Archila P; Cuello M; Karachaliou N; Rosell R; Arrieta O;
Thorac Cancer; 2019 Mar; 10(3):508-518. PubMed ID: 30706690
[TBL] [Abstract][Full Text] [Related]
27. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
[TBL] [Abstract][Full Text] [Related]
28. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Popat S; Curioni-Fontecedro A; Dafni U; Shah R; O'Brien M; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Nadal E; Janthur WD; López Castro R; García Campelo R; Rusakiewicz S; Letovanec I; Polydoropoulou V; Roschitzki-Voser H; Ruepp B; Gasca-Ruchti A; Peters S; Stahel RA
Ann Oncol; 2020 Dec; 31(12):1734-1745. PubMed ID: 32976938
[TBL] [Abstract][Full Text] [Related]
29. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with
Malignant Pleural Mesothelioma].
Zeng X; Jiang Z; Duan J
Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
[TBL] [Abstract][Full Text] [Related]
31. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
[TBL] [Abstract][Full Text] [Related]
32. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
[TBL] [Abstract][Full Text] [Related]
33. [Systemic Treatment of Malignant Pleural Mesothelioma].
Nakano T
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
[TBL] [Abstract][Full Text] [Related]
34. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
Arimura K; Hiroshima K; Nagashima Y; Nakazawa T; Ogihara A; Orimo M; Sato Y; Katsura H; Kanzaki M; Kondo M; Tagaya E
BMC Cancer; 2023 Dec; 23(1):1206. PubMed ID: 38062416
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab plus ipilimumab in malignant pleural mesothelioma.
Travert C; Tomasini P; Greillier L
Expert Rev Anticancer Ther; 2022 Aug; 22(8):815-822. PubMed ID: 35835722
[TBL] [Abstract][Full Text] [Related]
36. Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma.
Zhang D; Liang J; Lv Y; Huang X; Guo W
Medicine (Baltimore); 2022 Dec; 101(52):e32459. PubMed ID: 36596035
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
Baas P; Daumont MJ; Lacoin L; Penrod JR; Carroll R; Venkatesan S; Ubhi H; Calleja A; Snee M
Lung Cancer; 2021 Dec; 162():185-193. PubMed ID: 34823894
[TBL] [Abstract][Full Text] [Related]
38. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å
J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094
[TBL] [Abstract][Full Text] [Related]
39. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG
J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118
[TBL] [Abstract][Full Text] [Related]
40. Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.
de Lima VA; Sørensen JB
Med Oncol; 2015 Feb; 32(2):458. PubMed ID: 25572813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
